Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.39 |
| ▸ | MAPK14 | Q16539 | 9/20 | 0.35 |
| ▸ | PRKCI | P41743 | 1/20 | 0.34 |
| ▸ | NR3C2 | P08235 | 4/20 | 0.34 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.34 |
| ▸ | IGF1R | P08069 | 1/20 | 0.34 |
| ▸ | PROKR1 | Q8TCW9 | 1/20 | 0.33 |
| ▸ | PRKD1 | Q15139 | 2/20 | 0.33 |
| ▸ | PRKD2 | Q9BZL6 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22388259 | 0.75 | KDM4E (0.43) | HRH4MAPK14NR3C2MAPK10IGF1R | |
| SCHEMBL14270718 | 0.70 | NOS3 (0.48) | HRH4MAPK14NR3C2MAPK10IGF1R | |
| SCHEMBL2481330 | 0.69 | RECQL (0.47) | HRH4MAPK14NR3C2MAPK10IGF1R | |
| SCHEMBL17372006 | 0.69 | LOXL2 (0.47) | HRH4MAPK14NR3C2MAPK10IGF1R | |
| Hydrochloric Acid SCHEMBL31330323 | 0.68 | MAPK14 (0.40) | HRH4MAPK14NR3C2MAPK10IGF1R | |
| Hydrochloric Acid SCHEMBL2302210 | 0.65 | IGF1R (0.39) | HRH4MAPK14NR3C2MAPK10IGF1R | |
| SCHEMBL26550554 | 0.65 | HRH4 (0.59) | HRH4MAPK10 | |
| SCHEMBL20197170 | 0.63 | MAPK14 (0.42) | HRH4MAPK14MAPK10PROKR1 | |
| SCHEMBL29851369 | 0.61 | FDPS (0.59) | HRH4MAPK14MAPK10 | |
| SCHEMBL828257 | 0.61 | FDPS (0.59) | HRH4MAPK14MAPK10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230142274-A1 | SUBSTITUTED ARYL COMPOUND | NANJING ZAIMING PHARMACEUTICAL CO., LTD. (CN) | 2023-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230142274-A1 | SUBSTITUTED ARYL COMPOUND | RAD51, FANCI, BLM | HRH4 2886/4885MAPK14 821/4885PRKCI 3766/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.